- Home
- VRNA vs CLS Comparison
VRNA vs CLS Comparison
Compare VRNA & CLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNA
- CLS
- Stock Information
- Founded
- VRNA 2005
- CLS 1994
- Country
- VRNA United Kingdom
- CLS Canada
- Employees
- VRNA N/A
- CLS N/A
- Industry
- VRNA Biotechnology: Pharmaceutical Preparations
- CLS Electrical Products
- Sector
- VRNA Health Care
- CLS Technology
- Exchange
- VRNA Nasdaq
- CLS Nasdaq
- Market Cap
- VRNA 8.3B
- CLS 9.7B
- IPO Year
- VRNA 2017
- CLS 1998
- Fundamental
- Price
- VRNA $105.18
- CLS $194.74
- Analyst Decision
- VRNA Buy
- CLS Strong Buy
- Analyst Count
- VRNA 11
- CLS 10
- Target Price
- VRNA $114.10
- CLS $178.20
- AVG Volume (30 Days)
- VRNA 8.1M
- CLS 4.2M
- Earning Date
- VRNA 08-11-2025
- CLS 07-28-2025
- Dividend Yield
- VRNA N/A
- CLS N/A
- EPS Growth
- VRNA N/A
- CLS 55.91
- EPS
- VRNA N/A
- CLS 4.59
- Revenue
- VRNA $118,535,000.00
- CLS $10,587,200,000.00
- Revenue This Year
- VRNA $893.95
- CLS N/A
- Revenue Next Year
- VRNA $73.76
- CLS $13.73
- P/E Ratio
- VRNA N/A
- CLS $42.44
- Revenue Growth
- VRNA N/A
- CLS 20.52
- 52 Week Low
- VRNA $18.51
- CLS $40.25
- 52 Week High
- VRNA $105.50
- CLS $214.47
- Technical
- Relative Strength Index (RSI)
- VRNA 70.25
- CLS 71.30
- Support Level
- VRNA $104.58
- CLS $153.11
- Resistance Level
- VRNA $105.31
- CLS $214.47
- Average True Range (ATR)
- VRNA 0.22
- CLS 9.91
- MACD
- VRNA -0.64
- CLS 2.71
- Stochastic Oscillator
- VRNA 60.49
- CLS 67.85
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
About CLS Celestica Inc.
Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity & Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, The Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity & Cloud Solutions segment.